Lactobacillus reuteri against Helicobacter pylori: in vitro and in vivo efficacy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper discusses the evolution of eradication therapy. It emphasizes the efficacy and safety of Helinorm used alone and in combination with standard eradication therapy.

Full Text

Restricted Access

About the authors

Yu. Uspensky

Saint Petersburg State Pediatric Medical University; Acad. I.P. Pavlov First Saint Petersburg State Medical University

Email: baryshnikova_nv@mail.ru
Professor; MD

N. Baryshnikova

Acad. I.P. Pavlov First Saint Petersburg State Medical University; Institute of Experimental Medicine

Email: baryshnikova_nv@mail.ru
Candidate of Medical Sciences

References

  1. Blaser M. Hypothesis: changing relationships of Helicobacter pylori and humans: implications for health and disease // J. Infect. Dis. - 1999; 179 (6): 1523-30.
  2. Cohen H., Gramisu M., Fitzgibbons P. et al. Campylobacter pylori: associations with antral and fundal mucosal histology // Am. J. Gastroenterol. -1989; 84: 367-71.
  3. Hocker M., Hohenberger P. Helicobacter pylori virulence factors - one part of a big picture // Lancet. - 2003; 362 (9391): 1231-3.
  4. Malfertheiner P., Mégraud F., O’Morain C. Guidelines for the Management of Helicobacter Pylori Infection (2005). URL: https://061fb23c-fc26-4745-b739-1ba460436926.filesusr.com/ugd/d8d367_0d02c9a8554c476995c8bd67e47d0eca.pdf (дата обращения 06.12.2019).
  5. Stolte M., Eidit S., Ritter M. et al. Campylobacter pylori and gastritis // Pathologe. - 1989; 10: 21-6.
  6. Uspenskiy Y., Baryshnikova N., Smirnova A. et al. Prevalence of Helicobacter pylori infection in healthy volunteers and duodenal ulcer patients in St.-Petersburg, russia // J. Gastroenterol. Hepatol. - 2010; 25 (Suppl. 3): A43.
  7. Warren J., Marshall B. Unindentified curved bacilli on gastric epithelium in chronic gastritis // Lancet. - 1983; 1 (8336): 1273-5.
  8. Marshall B., Armstrong J., McGechie D. et al. Attempt to fulfil Koch’s postulates for pyloric Campylobacter // Med. J. Australia. - 1985; 142 (8): 436-9.
  9. Marshall B., Armstrong J., Francis G. et al. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis // Digestion. - 1987; 37 (suppl. 2): 16-30.
  10. Marshall B., McGechie D., Rogers P. et al. Pyloric Campylobacter infection and gastroduodenal disease // Med. J. Australia. - 1985; 142 (8): 439-44.
  11. Ciccaglione A., Cellini L., Grossi L. et al. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study // Helicobacter. - 2015. doi: 10.1111/hel.12209.
  12. George L., Borody T., Andrews P. et al. Cure of duodenal ulcer after eradication of Helicobacter pylori // Med J Aust. - 1990; 153 (3): 145-9.
  13. Iser J., Buttigieg R., Iseli A. Low dose, short duration therapy for the eradication of Helicobacter pylori in patients with duodenal ulcer // Med. J. Aust. - 1994; 160 (4): 192-6.
  14. Wagner S., Varrentrapp M., Haruma K. et al. The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection // Z. Gastroenterol. - 1991; 29 (11): 595-8.
  15. Bazzoli F., Pozzato P. Therapy of H. pylori infection // J. Physiol. Pharmacol. - 1997; 48 (Suppl. 4): 39-46.
  16. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group // Gut. - 1997; 41: 8-13.
  17. Malfertheiner P., Mégraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report // Aliment. Pharmacol. Ther. - 2002; 16: 167-180.
  18. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. - 2007; 56: 772-81. doi: 10.1136/gut.2006.101634.
  19. Malfertheiner P. et al. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report // Gut. - 2012; 61: 646-64.
  20. Malfertheiner P., Megraud F., O’Morain C. et al. On behalf of the European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report // Gut. - 2017; 66: 6-30. doi: 10.1136/gutjnl-2016-312288.
  21. Успенский Ю.П., Суворов А.Н., Барышникова Н.В. Инфекция Helicobacter pylori в клинической практике / СПб: ИнформМед, 2011; с. 497-537
  22. Успенский Ю.П., Суворов А.Н., Барышникова Н.В. Инфекция Helicobacter pylori в клинической практике / СПб, ИнформМед, 2011; 497-506
  23. Szajewska H. Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment. Pharmacol. Ther - 2010; 32: 1069-79.
  24. Molina-Infante J., Gisbert J. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time // Rev. Esp. Enferm. Dig. - 2013; 105 (8): 441-4.
  25. Tong J., Ran Z., Shen J. et al. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy // Aliment. Pharmacol. Ther. - 2007; 25: 155-68.
  26. Wang Z., Gao Q., Fang J. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy // J. Clin. Gastroenterol. -2013; 47: 25-32.
  27. Sachdeva A., Nagpal J. Meta-analysis: Efficacy of bovine lactoferrin in Helicobacter pylori eradication // Aliment. Pharmacol. Ther. - 2009; 29: 720-30.
  28. Zou J., Dong J., Yu X. Meta-analysis: The effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy // Helicobacter. - 2009; 14: 119-27.
  29. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials // Eur. J. Gastroenterol. Hepatol. - 2009; 21: 45-53.
  30. Dinleyici E., Kara A., Ozen M. et al. Saccharomyces boulardii CNCM I-745 in different clinical conditions // Expert Opin. Biol. Ther. - 2014; 14: 1593-609.
  31. Козлова Д.И. Состояние кишечного микробиоценоза и течение H. pylori-ассоциированного гастрита в условиях эрадикационной и синбиотической терапии. Автореф. дисс.. канд. мед. наук. СПб, 2004; 21 с.
  32. Canducci F., Cremonini F., Armuzzi A. et al. Probiotics and Helicobacter pylori eradication. // Dig. Liver Dis.: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. - 2002; 34 (suppl. 2): 81-3.
  33. Суворов А.Н., Барышникова Н.В., Сварваль А.В. и др. Возможности некоторых пробиотических штаммов вэ радикации Helicobacter pylori in vitro и in vivo // Фарматека. - 2018; 2 (355): 74-8 DOI: https://dx.doi.org/10.18565/pharmateca.2018.2.74-78.
  34. Holz C., Busjahn A., Mehling H. et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study // Probiotics Antimicrob. Proteins. - 2015; 7 (2): 91-100. doi: 10.1007/s12602-014-9181-3.
  35. Mehling H., Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans // Nutrients. - 2013; 5: 3062-73.
  36. Francavilla R., Polimeno L., Demichina A. et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebocontrolled study // J. Clin. Gastroenterol. - 2014; 48 (5): 407-13. doi: 10.1097/MCG.0000000000000007.
  37. Dore M., Cuccu M., Pes G. et al. Lactobacillus reuteri in the treatment of Helicobacter pylori infection // Intern. Emerg. Med. - 2014; 9 (6): 649-54. doi: 10.1007/s11739-013-1013-z.
  38. Muresan I., Pop L., Dumitrascu D. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia // Med. Pharm. Rep. - 2019; 92 (4): 352-5. doi: 10.15386/mpr-1375.
  39. Бордин Д.С., Войнован И.Н., Хомерики С.Г. и др. Эффективность и безопасность пробиотических бактерий Lactobacillus reuteri DSMZ17648 у инфицированных Helicobacter pylori, не имеющих абсолютных показаний для эрадикационной терапии: результаты исследования // Лечащий врач. - 2016; 5 URL: https://www.lvrach.ru/2016/05/15436483/ (дата обращения 06.12.2019).
  40. Паролова Н.И., Корниенко Е.А., Антонов П.В. и др. Инновационный подход в терапии инфекции Н. pylori у детей // РМЖ. - 2015; 22: 1339-40
  41. Успенский Ю.П., Фоминых Ю.А., Иванов С.В. и др. Эволюция в эрадикационной терапии НР-ассоциированных заболеваний. Выход за рамки стандартов? // РМЖ. - 2016; 17: 1144-52
  42. Успенский Ю.П., Барышникова Н.В., Фоминых Ю.А. Лечение инфекции Helicobacter pylori: проблемы и перспективы // Consilium Medicum. Гастроэнтерология. (Прил.). - 2015; 1: 8-17
  43. Ткаченко Е., Успенский Ю., Барышникова Н. Оптимизация лечения заболеваний, ассоциированных с Helicobacter pylori // Врач. - 2012; 1: 36-8

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies